NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive to Host Investor Morning on May 12, 2009

- Includes Surgeon Panel, Strategic Updates, and Product Showcase -
- St. Regis Hotel, New York, 7:30 to 10:30 a.m. ET -

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host a meeting for investors and analysts at the St. Regis Hotel, 2 East 55th St., New York, NY on Tuesday, May 12, 2009 from 7:30 to 10:30 a.m. ET.

The agenda will include key updates from management, surgeon panel presentations, audience Q&A with both management and surgeons, and hands-on product demonstrations. Alex Lukianov, Chairman and Chief Executive Officer, will open the meeting with a company update and then moderate a surgeon panel with presentations and forum discussion on the following topics:

-- The economy's impact on a spine surgeon's practice and future outlook
-- Broad application of XLIF(R) to address increasing number of indications
-- Advantages of XLIF and the lateral approach vs traditional surgery, including physician insight into patient and economic benefits
-- Outcome comparison of XLIF enabled with NeuroVision(R) vs other lateral techniques
-- Surgeon perspective on reimbursement environment for spine surgery
-- Experience with recent product additions in biologics and cervical motion preservation

The surgeon panel will be followed by a product strategy overview and demonstration by NuVasive management including updates on NuVasive's Osteocel(R) Plus biologic and the recent acquisition of Cervitech(R) Inc., with its investigational PCM(R) cervical disc system. Various product booths will be available for attendees to experience a hands-on demonstration with the unique opportunity to speak with both NuVasive management and presenting surgeons.

NuVasive is honored to have the participation of the following leading spine surgeons:

-- Dr. Christopher R. Brown, Duke University Medical Center
-- Dr. Andrew Cappuccino, Buffalo Spine Surgery
-- Dr. Eric Elowitz, NYC Neurosurgery
-- Dr. James Hale, Eastern Orthopedic Associates
-- Dr. Robert Isaacs, Duke University Medical Center
-- Dr. W. Blake Rodgers, Spine Midwest, Inc.
-- Dr. William Smith, Western Regional Center for Brain & Spine Surgery

Several members of NuVasive executive management will be in attendance including:

-- Alex Lukianov, Chairman and Chief Executive Officer
-- Keith Valentine, President and Chief Operating Officer
-- Kevin O'Boyle, Executive Vice President and Chief Financial Officer

A live webcast of the meeting will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With nearly 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


    Contact:                                Investors:
    Kevin C. O'BoylePatrick F. Williams
    EVP & Chief Financial Officer           Vice President, Finance & Investor
    NuVasive, Inc.                          Relations
    858-909-1998                            NuVasive, Inc.investorrelations@nuvasive.com          858-638-5511
                                            investorrelations@nuvasive.com

                                            Media:
                                            Jason RandoThe Ruth Group
                                            646-536-7025
                                            jrando@theruthgroup.com

SOURCE NuVasive, Inc.
05/06/2009
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer, +1-858-909-1998, or Investors, Patrick F. Williams, Vice President, Finance & Investor Relations, +1-858-638-5511, both of NuVasive, Inc., investorrelations@nuvasive.com; or Media, Jason Rando, The Ruth Group, +1-646-536-7025, jrando@theruthgroup.com
Web Site: http://www.nuvasive.com